𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Effect of the potent aromatase inhibitor letrozole on lipid parameters in postmenopausal women with breast cancer

✍ Scribed by E. Bairaktari; M. Elisaf; K. Nikolaides; V. Kakaidi; A. Katsaraki; N. Pavlides

Book ID
119434899
Publisher
Elsevier Science
Year
2000
Tongue
English
Weight
280 KB
Volume
151
Category
Article
ISSN
0021-9150

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

Use of aromatase inhibitors in postmenop
Use of aromatase inhibitors in postmenopausal women with advanced breast cancer
✍ Roseman, Barry J.; Buzdar, Aman U.; Singletary, S. Eva πŸ“‚ Article πŸ“… 1997 πŸ› John Wiley and Sons 🌐 English βš– 39 KB πŸ‘ 2 views

Surgeons have been involved in the management of metastatic breast cancer since the technique of ovarian ablation was introduced in 1896. However, as newer hormonal and chemotherapeutic regimens were developed, drug therapy gradually replaced surgery as the preferred treatment for metastatic breast

Effect of the potent aromatase inhibitor
Effect of the potent aromatase inhibitor fadrozole hydrochloride (CGS 16949A) in postmenopausal women with breast carcinoma
✍ Luis A. M. Costa; Michael S. Kopreski; Laurence M. Demers; Vernon M. Chinchilli; πŸ“‚ Article πŸ“… 1999 πŸ› John Wiley and Sons 🌐 English βš– 58 KB πŸ‘ 1 views

## Background: Fadrozole hydrochloride (cgs 16949a) is a highly potent, nonsteroidal aromatase inhibitor that significantly lowers estrogen levels in postmenopausal women and can be effective therapy for patients with advanced hormone-dependent breast carcinoma. circulating estradiol, estrone, and

Summary of aromatase inhibitor clinical
Summary of aromatase inhibitor clinical trials in postmenopausal women with early breast cancer
✍ Aman U. Buzdar; R. Charles Coombes; Paul E. Goss; Eric P. Winer πŸ“‚ Article πŸ“… 2008 πŸ› John Wiley and Sons 🌐 English βš– 115 KB

Five years of adjuvant therapy with tamoxifen was considered the gold-standard treatment for postmenopausal women with estrogen receptor-positive breast cancer for many years. Data from a core group of clinical trials investigating the safety and efficacy of aromatase inhibitors (AIs) have challenge